INTRODUCTION {#s1}
============

Epithelial ovarian cancer (EOC) is the 5th leading cause of cancer-related deaths among women and it is estimated that 22,240 new diagnoses and 14,070 deaths will occur in 2018 in the United States \[[@B1]\]. Due to its asymptomatic nature, more than half of patients are diagnosed with advanced-stage diseases. Although most patients respond to the initial treatment of debulking surgery followed by platinum-based chemotherapy, more than 70% develop recurrence within 5 years. Various prognostic factors in EOC patients have been reported: clinical stage, tumor histology, tumor grade, size of residual tumor after initial surgery or platinum resistance \[[@B2]--[@B4]\]. However there are limited predictors that can be used to estimate a patient's survival prior to the initiation of treatment.

The prognostic nutritional index (PNI) was developed in 1984 and originally used for risk assessment of post-surgical complications \[[@B5]\]. PNI has recently attracted attention as an indicator of a poor prognosis in patients with various solid cancers \[[@B6]--[@B9]\]. However, to our knowledge, only two studies have investigated the significance of PNI in EOC patients ([Table 1](#T1){ref-type="table"}) \[[@B10], [@B11]\]. In 2016, Miao et al. reported that decreased PNI was significantly correlated with shorter PFS (HR, 1.890; 95%CI, 1.396-2.560; p\<0.001) and OS (HR, 1.747; 95%CI, 1.293-2.360; p\<0.001) in patients with EOC \[[@B10]\]. Although this study included a relatively large number of patients (n=344), the authors did not evaluate the prognostic significance of PNI according to clinical stage \[[@B10]\]. The following year, Zhang et al. showed that decreased PNI was significantly correlated with shorter PFS and OS in advanced-stage EOC patients (Stage III: PFS p\<0.001, OS p\<0.001, Stage IV: PFS p=0.005, OS p=0.010). In multivariate analysis, they also showed that decreased PNI was an independent predictor of shorter PFS (HR, 1.815; 95%CI, 1.113-2.958; p=0.0017) and OS (HR, 1.699; 95%CI, 1.035-2.789; p=0.0036) only in stage III EOC patients \[[@B11]\]. However, the number of stage I, II and IV EOC patients included in this study was relatively small \[[@B11]\]. Thus, the prognostic significance of PNI in early- or advanced-stage EOC patients remains unclear.

###### Summary of studies investigating the significance of PNI in EOC patients

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                  Year   Number of patients   Cut off value (PNI)   Conclusion            Analyses according to clinical stage                                            Multivariate analysis   
  ------------------------ ------ -------------------- --------------------- --------------------- ------------------------------------------------------------------------------- ----------------------- -----
  Miao et al \[[@B10]\]    2016   168                  176                   45                    Decreased PNI is associated with poor PFS and OS.                               No                      Yes

  Zhang et al \[[@B11]\]   2017   67                   170                   47.2                  Decreased PNI is associated with poor PFS and OS only in stage III OC.          Yes                     Yes

  Current study            2018   164                  144                   Early stage 44.7\     Decreased PNI is associated with poor PFS and DSS only in advanced-stage EOC.   Yes                     Yes
                                                                             Advanced stage 42.9                                                                                                           
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: PNI; Prognostic nutritional index, PFS; Progression-free survival, OS; Overall survival, DSS; Disease-specific survival, EOC; Epithelial ovarian cancer.

In the current study, we investigated the prognostic significance of pretreatment PNI in Japanese women with EOC according to the clinical stage.

RESULTS {#s2}
=======

Definition of decreased PNI according to clinical stage {#s2_1}
-------------------------------------------------------

ROC curves were described to select the optimal cut-off value for PNI in early- and advanced-stage patients ([Figure 1A, 1B](#F1){ref-type="fig"}). The cut-off values of PNI for recurrence and survival were 44.7 and 42.9 in early- and advanced-stage patients, respectively. The area under the ROC curve (AUC) for predicting recurrence and survival was 0.5158 (95%CI, 0.3546-0.6738) and 0.7323 (95%CI, 0.4505-0.9012), respectively, in early-stage patients, and 0.6734 (95%CI, 0.5627-0.7675) and 0.7752 (95%CI, 0.6790-0.8490), respectively, in advanced-stage patients.

![ROC curves for recurrence and survival and cut-off value of prognostic nutritional index (PNI) according to clinical stage\
**(A)** ROC curves for (i) recurrence and (ii) survival at 2 years for PNI at early stage. **(B)** ROC curves for (i) recurrence and (ii) survival at 2 years for PNI at advanced stage.](oncotarget-10-3605-g001){#F1}

Prognostic significance of PNI in early EOC patients {#s2_2}
----------------------------------------------------

The characteristics of early-stage EOC patients are shown according to PNI in [Table 2](#T2){ref-type="table"}. Among the 164 patients with early-stage disease, 44 (26.8%) displayed PNI less than 44.7 at the time of initial diagnosis. Optimal surgery was performed for all early-stage patients. Although there were no differences in age, histology or presence of ascites, decreased PNI was significantly correlated with elevated CA125 (p=0.0159). In the survival analyses, as shown in [Figure 2A](#F2){ref-type="fig"} and [Table 3](#T3){ref-type="table"}, decreased PNI was not significantly correlated with short PFS (p=0.5778) or DSS (p=0.9864) in early-stage EOC patients. In the multivariate analysis, a decreased PNI was not associated with a shorter PFS (HR, 0.66; 95%CI, 0.21-1.76; p=0.4169) or DSS (HR, 0.77; 95%CI, 0.15-3.04; p=0.7184) in early-stage EOC patients ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

###### Clinicopathological characteristics of early-stage patients according to PNI

  -------------------------------------------------------------------------------------
                                    All patients\   PNI\< 44.7\   PNI≥44.7\    
                                    (n=164)         (n=44)        (n=120)      
  ------------------ -------------- --------------- ------------- ------------ --------
  Age (years)        \<50           64              21 (32.8)     43 (67.2)    0.1665

                     ≥51            100             23 (23.0)     77 (77.0)    

  Histology          Serous         24              8 (33.3)      16 (66.7)    0.0164

                     Clear cell     62              22 (35.5)     40 (64.5)    

                     Endometrioid   42              10 (23.8)     32 (76.2)    

                     Mucinous       24              0             24 (100)     

                     Others         12              4 (33.3)      8 (66.7)     

  Ascites (ml) ^1^   None           127             30 (23.6)     97 (76.4)    0.2649

                     \<2000         27              10 (37.0)     17 (63.0)    

                     ≥2000          2               1 (50.0)      1 (50.0)     

  Optimal surgery    Yes            164             44 (26.8)     120 (73.2)   

                     No             0               0             0            

  CA125 (U/ml)       \<500          135             31 (20.0)     104 (80.0)   0.0159

                     ≥500           29              13 (44.8)     16 (55.2)    
  -------------------------------------------------------------------------------------

Abbreviations: PNI; Prognostic nutritional index, CA125; carbohydrate antigen 125.

The amount of ascites was not indicated for 8 cases.

![Clinical implications of prognostic nutritional index (PNI) in EOC patients\
**(A)** Significance of PNI in patients at early stage. (i) Kaplan--Meier estimates of progression-free survival at early stage (PNI: ≥44.7 vs. \<44.7). (ii) Kaplan--Meier estimates of disease-specific survival at early stage (PNI: ≥44.7 vs. \<44.7). **(B)** Significance of PNI in patients at advanced stage. (i) Kaplan--Meier estimates of progression-free survival at advanced stage (PNI: ≥42.9 vs. \<42.9). (ii) Kaplan--Meier estimates of disease-specific survival at advanced stage (PNI: ≥42.9 vs. \<42.9).](oncotarget-10-3605-g002){#F2}

###### Univariate analysis of prognostic factors for progression-free survival and disease-specific survival of early-stage patients based on PNI

                                  PFS    DSS                                     
  ------------------ ------------ ------ ----------- -------- ------ ----------- --------
  Age (years)        \<50         1                           1                  
                     ≥51          1.40   0.28-1.71   0.4513   1.33   0.37-5.25   0.6626
  Histology          Serous       1                           1                  
                     Non serous   1.97   0.64-5.11   0.2159   0.68   0.04-3.73   0.7043
  Ascites (ml) ^1^   None         1                           1                  
                     \<2000       1.20   0.39-3.12   0.7334   1.35   0.28-5.03   0.6737
                     ≥2000        NA                          NA                 
  CA125(U/ml)        \<500        1                           1                  
                     ≥500         3.04   1.20-7.23   0.0202   2.06   0.44-7.40   0.3230
  PNI                ≥44.7        1                           1                  
                     \<44.7       0.72   0.23-1.84   0.5089   0.99   0.21-3.57   0.9847

Abbreviations: CI; confidence interval, CA125; carbohydrate antigen 125, PNI; Prognostic nutritional index, NA; not available.

The amount of ascites was not indicated for 8 cases.

Prognostic significance of PNI in advanced EOC patients {#s2_3}
-------------------------------------------------------

The characteristics of advanced-stage EOC patients are shown according to PNI in [Table 4](#T4){ref-type="table"}. Among the 144 patients with advanced-stage disease, 81 (56.3%) displayed PNI less than 42.9 at the time of initial diagnosis. Although there were no differences in age or histology, decreased PNI was significantly correlated with large amount of ascites (p\<0.0001), a lower optimal surgery rate (p=0.0127) and elevated CA125 (p=0.0004). As shown in [Figure 2B](#F2){ref-type="fig"}, decreased PNI was significantly correlated with a shorter PFS (p\<0.0001) and DSS (p\<0.0001) in advanced-stage patients. Multivariate analysis showed that in addition to a low optimal surgery rate, decreased PNI was an independent prognostic factor for PFS ([Table 5](#T5){ref-type="table"}: HR, 2.24; 95%CI, 1.18-4.25; p=0.0139) and DSS in advanced-stage patients ([Table 6](#T6){ref-type="table"}: HR, 2.85; 95%CI, 1.16-7.11; p=0.0217).

###### Clinicopathological characteristics of advanced-stage patients according to PNI

  -----------------------------------------------------------------------------------------
                                       All patients\   PNI\< 42.9\   PNI≥42.9\   
                                       (n=144)         (n=81)        (n= 63)     
  --------------------- -------------- --------------- ------------- ----------- ----------
  Age (years)           \<50           37              21(56.8)      16 (43.2)   0.9425

                        ≥51            107             60 (56.1)     47 (43.9)   

  Histology             Serous         92              50 (54.3)     42 (45.7)   0.1349

                        Clear cell     16              12 (75.0)     4 (25.0)    

                        Endometrioid   11              3 (27.3)      8 (72.7)    

                        Mucinous       4               3 (75.0)      1 (15.0)    

                        Others         21              13 (61.9)     8 (38.1)    

  Ascites (ml) ^1^      None           60              16 (26.7)     44 (73.3)   \<0.0001

                        \<2000         38              27 (71.1)     11 (29.0)   

                        ≥2000          28              25 (89.3)     3 (10.7)    

  Optimal surgery ^2^   Yes            76              33 (43.4)     43 (56.6)   0.0127

                        No             55              36 (65.5)     19 (34.5)   

  CA125 (U/ml)          \<500          63              25 (39.7)     38 (60.3)   0.0004

                        ≥500           81              56 (69.1)     25 (30.9)   
  -----------------------------------------------------------------------------------------

Abbreviations: PNI; Prognostic nutritional index, CA125; carbohydrate antigen 125.

The amount of ascites was not indicated for 18 cases.

Surgery was performed in 131 cases.

###### Univariate/ Multivariate analysis of prognostic factors for progression-free survival of advanced-stage patients based on PNI

                                     Univariate analysis   Multivariate analysis                                 
  --------------------- ------------ --------------------- ----------------------- ---------- ------ ----------- --------
  Age (years)           \<50         1                                                                           
                        ≥51          1.41                  0.87-2.41               0.1667                        
  Histology             Serous       1                                                                           
                        Non serous   0.99                  0.65-1.55               0.9783                        
  Ascites (ml) ^1^      None         1                                                        1                  
                        \<2000       1.63                  0.97-2.72               0.0648     1.09   0.57-2.07   0.7983
                        ≥2000        2.08                  1.15-3.67               0.0169     1.16   0.52-2.54   0.7177
  Optimal surgery ^2^   Yes          1                                                        1                  
                        No           2.40                  1.53-3.76               0.0001     2.02   1.22-3.34   0.0065
  CA125(U/ml)           \<500        1                                                                           
                        ≥500         1.47                  0.97-2.26               0.0677                        
  PNI                   ≥42.9        1                                                        1                  
                        \<42.9       2.92                  1.89-4.60               \<0.0001   2.24   1.18-4.25   0.0139

Abbreviations: CI; confidence interval, CA125; carbohydrate antigen 125, PNI; Prognostic nutritional index.

The amount of ascites was not indicated for 18 cases.

Surgery was performed in 131 cases.

###### Univariate/ Multivariate analysis of prognostic factors for disease-specific survival of advanced-stage patients based on PNI

                                     Univariate analysis   Multivariate analysis                                 
  --------------------- ------------ --------------------- ----------------------- ---------- ------ ----------- --------
  Age (years)           \<50         1                                                                           
                        ≥51          1.46                  0.80-2.86               0.2254                        
  Histology             Serous       1                                                                           
                        Non serous   0.63                  0.38-1.04               0.0705                        
  Ascites (ml) ^1^      None         1                                                        1                  
                        \<2000       1.42                  0.72-2.77               0.3060     0.76   0.30-1.92   0.5613
                        ≥2000        2.68                  1.33-5.33               0.0067     1.69   0.63-4.74   0.2990
  Optimal surgery ^2^   Yes          1                                                        1                  
                        No           2.70                  1.56-4.76               0.0004     2.53   1.30-5.03   0.0065
  CA125(U/ml)           \<500        1                                                                           
                        ≥500         1.27                  0.77-2.14               0.3449                        
  PNI                   ≥42.9        1                                                        1                  
                        \<42.9       3.74                  2.14-6.93               \<0.0001   2.85   1.16-7.11   0.0217

Abbreviations: CI; confidence interval, CA125; carbohydrate antigen 125, PNI; Prognostic nutritional index.

The amount of ascites was not indicated for 18 cases.

Surgery was performed in 131 cases.

DISCUSSION {#s3}
==========

In the current study, we showed that PNI was an independent prognostic factor for short PFS and DSS in advanced-stage EOC patients. We also demonstrated that PNI is not a prognostic indicator in early-stage EOC patients.

Including ours, three studies have investigated the significance of PNI in EOC patients. As shown in [Table 1](#T1){ref-type="table"}, PNI was found to be an independent prognostic indicator in EOC patients in all of these studies. Of note, 2 studies, including ours, that evaluated the prognostic significance of PNI according to clinical stage suggested that PNI is an independent prognostic indicator in advanced-stage EOC patients. In both studies, however, PNI did not provide any prognostic information for early-stage EOC patients \[[@B10], [@B11]\]. Collectively, these results strongly indicate that PNI can serve as a prognostic indicator only in advanced-stage EOC patients.

PNI is calculated by the serum albumin and absolute lymphocyte counts (ALC). Albumin is the most abundant plasma protein in humans. Low serum albumin reflects the nutritional status of patients or an increased leakage of albumin into the extravascular space, which results in hypoalbuminemia, pleural effusion, or edema. Thus, hypoalbuminemia is more frequently observed in advanced- than in early-stage EOC patients. Hypoalbuminemia may also reflect the inflammatory activity induced by cytokines such as interleukin-6 (IL-6) or tumor necrosis factor \[[@B12]\]. Moreover, it has been reported that inflammation can also decrease ALC. In mice, IL-6 was demonstrated to inhibit lymphopoiesis, leading to the increased production of myeloid cells \[[@B13]\]. In fact, decreased ALC significantly correlates with increased serum levels of IL-6 or IL-2 in patients with soft tissue sarcoma \[[@B14]\]. In the current study, decreased PNI was observed in both early- and advanced-stage EOC patients. We speculate that cytokine production (i.e., IL-6) by EOC cells causes both hypoalbuminemia and decreased ALC, leading to decreased PNI. In the current study, early-stage patients had a significantly higher PNI than advanced-stage patients (average PNI; 46.5 versus 40.3, p\<0.0001). Accordingly, decreased PNI was more frequently observed in advanced- compared with early-stage patients (56.3% vs. 26.8%, respectively, p\<0.001). A decreased PNI in advanced-stage EOC patients has also been reported in previous studies \[[@B11]\]. This may be explained by the increased production of cytokines from larger advanced tumors and the increased leakage of albumin from the highly-developed tumor vasculatures. Although previous studies employed only one cut-off value for both early- and advanced-stage patients \[[@B10], [@B11]\], we believe that the optimal cut-off value of PNI should be determined according to clinical stages. As shown in [Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}, we determined the cut-off values of PNI in early- and advanced-stage patients separately from ROC curves in the current study (44.7 in early-stage and 42.9 in advanced-stage patients). As the optimal PNI cut-off values were employed for both early- and advanced-stage EOC patients, we believe that we were able to draw a definitive conclusion regarding the prognostic significance of PNI in EOC patients.

The reason for the poor prognosis of EOC patients with decreased PNI remains unknown. However, both low ALC \[[@B15]\] and hypoalbuminemia \[[@B16]\] have been reported to be associated with shorter survival in patients with EOC, which frequently expresses IL-6 \[[@B17]\]. As there is a positive correlation between tumor-infiltrating lymphocytes and ALC \[[@B15], [@B18]\] or the albumin level \[[@B19]\], PNI might influence the survival outcome through an immunological mechanism.

The results of the present study may have important clinical implications. First, pretreatment PNI offers individualized survival estimates ([Figure 2](#F2){ref-type="fig"}). Considering the fact that pretreatment PNI does not provide prognostic information for early-stage patients, PNI should only be evaluated in advanced EOC patients. Second, calculation of pretreatment PNI may enable physicians to offer closer follow-up for advanced patients displaying decreased PNI. Third, as PNI calculation requires only low-cost peripheral blood examinations, PNI can be used universally for survival estimation on managing EOC patients.

The limitations of our study need to be addressed. First, this study was conducted at a single institution. Second, this was a retrospective study. We intend to verify our clinical findings in collaborative multi-institutional studies in a prospective setting. The last limitation is the cut-off values of PNI. In the present study, the cut-off values of PNI for recurrence and survival were defined as 44.7 in early-stage patients and 42.9 in advanced-stage patients, respectively. The cut-off values for PNI in previous studies of EOC ranged between 45 and 47.2 ([Table 1](#T1){ref-type="table"}), which are slightly higher than our cut-off values. The reason for the difference in cut-off values remains unknown; however, the baseline PNI in cancer patients may differ due to ethnicity. Thus, the threshold for PNI need to be further investigated in future studies.

In conclusion, the decreased PNI at the time of initial diagnosis is a predictor of recurrence and shorter survival in advanced EOC patients. Future prospective investigations are warranted for the clinical applications of PNI in EOC patients.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

Permission to proceed with data acquisition and analysis was obtained from the institutional review board of Osaka University Hospital. A list of patients who were diagnosed with epithelial ovarian cancer and treated at Osaka University Hospital between April 2007 and March 2016 was generated from our institutional registry, and the clinical data were analyzed.

Treatment and post-treatment follow-up {#s4_2}
--------------------------------------

Patients were clinically staged according to the International Federation of Gynecology and Obstetrics (FIGO) staging criteria. The standard procedures for primary cytoreductive surgery consisted of total abdominal hysterectomy (TAH), bilateral salpingo-oophorectomy (BSO), omentectomy, and pelvic and para-aortic lymphadenectomy sampling. In cases with gross unresectable tumors in the peritoneal cavity, retroperitoneal lymphadenectomy was not performed. Postoperative adjuvant chemotherapy consisted of paclitaxel (175 mg/m^2^), and carboplatin (area under the curve: 5) was initiated within 6 weeks of primary cytoreductive surgery when required. Patients with advanced-stage diseases who received platinum-based neo-adjuvant chemotherapy (NAC) instead of primary cytoreductive surgery were also included in this study. Interval debulking surgery was performed whenever possible. The definition of optimal debulking surgery was ≤1 cm being the largest tumor burden remaining at the completion of cytoreduction. Additional surgical procedures such as partial resection of gastrointestinal tract, liver, diaphragm or urinary tract were performed when it was considered necessary to achieve optimal debulking surgery. After the initial treatment, follow-up examinations were conducted by gynecological oncologists at regular intervals in an outpatient clinic.

Definition of PNI {#s4_3}
-----------------

During the period between the initial diagnosis and start day of the initial treatment, all patients underwent at least 2 blood tests including complete blood counts. PNI was calculated according to the following formula: 10 × serum albumin (g/L) + 0.005 × lymphocyte count (per mm^3^) in the peripheral blood. The cut-off value of PNI was defined based on the maximum Youden index (i.e., sensitivity+specificity-1) in the time- dependent receiver operating characteristics (ROC) curve for recurrence and survival.

Evaluation of ascites volume {#s4_4}
----------------------------

The amount of ascites before treatment was evaluated by five-point method using computed tomography (CT), as reported previously \[[@B20], [@B21]\]. Briefly, the thickness of ascites in centimeters was measured in three planes such as the bilateral subphrenic space (A and B), the bilateral paracolic space (C and D) and the pre-bladder space (E). The amount of ascites was calculated by following equation; (A+B+C+D+E) x 200 (ml). Amount of ascites could not be evaluated in 26 cases because pretreatment CT were taken at other hospitals.

Statistical analysis {#s4_5}
--------------------

Continuous data were compared between the groups using Student's *t*-test, Wilcoxon rank-sum test, or median test. Frequency counts and proportions were compared between groups using the chi-square test or a two-tailed Fisher's exact test. We performed univariate analysis by comparing the Kaplan--Meier curves for each subgroup with the log-rank test. Progression-free survival (PFS) was defined as the time from the date of the initial surgical procedure or chemotherapy to the date of the first physical or radiographic evidence of disease progression. Disease-specific survival (DSS) was defined as the time from the date of treatment to the date of cancer-related death. P-values of \<0.05 were considered significant. All analyses were performed using JMP® software, version 12.0 (SAS Institute, Cary, NC, USA).

SUPPLEMENTARY MATERIALS TABLE {#s5}
=============================
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